SYM FINANCIAL Corp Purchases 364 Shares of Eli Lilly and Company (NYSE:LLY)

SYM FINANCIAL Corp increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,141 shares of the company’s stock after buying an additional 364 shares during the period. Eli Lilly and Company accounts for 0.6% of SYM FINANCIAL Corp’s holdings, making the stock its 18th biggest holding. SYM FINANCIAL Corp’s holdings in Eli Lilly and Company were worth $3,580,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Simon Quick Advisors LLC boosted its holdings in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at $363,000. Terril Brothers Inc. lifted its stake in shares of Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp lifted its stake in shares of Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Eli Lilly and Company by 5.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock valued at $206,683,000 after buying an additional 17,461 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Stock Performance

NYSE:LLY traded down $20.94 on Friday, hitting $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The business’s 50-day simple moving average is $761.06 and its two-hundred day simple moving average is $671.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the previous year, the firm posted $1.62 EPS. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.